The Mainz-based company, Biontech, and the US group Pfizer, have partnered with the UK’s first supply agreement to a possible, just in-development-Corona vaccine.
Subject to regulatory approval, or authorization of 30 million doses of the vaccine candidates " to;BNT 162" be delivered, expected in the years 2020 and 2021, as the company said on Monday. Financial Details were not disclosed. "We are in advanced talks with several other governments, and we hope to können" soon for more supply agreements to announce;, Biontech co-founder and chief Ugur Sahin said, according to the message.
Read more about Coronavirus in the News-Ticker of FOCUS Online.
To run a total of four RNA vaccine candidates of Biontech and Pfizer studies of Phase I and II For two of these candidates currently in the USA and in Germany, the US food and drug administration approved procedure FDA recently an accelerated approval.
Biontech and Pfizer called first results of the study "ermutigend"
The first results of the previous studies in the USA have placed Biontech and Pfizer already open and they called "ermutigend", several experts spoke of positive results. Subjects – a total of 45 healthy people aged 18 to 55 years of age had antibodies against the causative agent of Sars-CoV-2 developed. However, it is unclear whether these antibodies actually protect against infection. The show Tests with up to 30,000 subjects.
Now, the company said this month it might go off with the other trials in phases IIb and III, with a main candidates for the vaccine. If this course is successful, could be applied for in October of the admission procedure. From the Tests in Germany, first results, you will be expected to take place in July.
Temperatures soar to the top: the Azores brings up the long-awaited summer
The Weather Channel temperatures soar to the top: the Azores high brings the long-awaited summer
